Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy

Inclusion Criteria: * Provide written (personally signed and dated) informed consent before completing any study-related procedure, which means any assessment or evaluation that would not have formed a part of her normal medical care. * Be a female who has or is suspected to have endometriosis * Greater than or equal to 18 years of age and less than 42years. * Scheduled to undergo laparoscopy. * According to the local practice the women should sign a specific clause on avoiding pregnancy based on the use of two effective methods for birth control (condom and spermicidal) following 30 days after the last dose/application. * Be non-pregnant undergoing laparoscopy for confirmed or suspected endometriosis within first 10 days of her cycle. * Have a body mass index (BMI) \< 32 kg/m2 Exclusion Criteria: If any of the following criteria apply, the subject MUST NOT be admitted/continue the study trial. The subject: * Is pregnant (if positive-Urine pregnancy test at screening) or lactating; * Has evidence of drug or alcohol abuse. * Have used hormonal replacement therapy or Danazol therapy within the past 8 weeks before study entry * Has any of the following: Epileptic Seizure, Migraine Headache, Angina, Chronic Heart Failure, Obstruction of a Blood Vessel by a Blood Clot, Liver Problems, Kidney Disease, Pregnancy, Combined High Blood Cholesterol and Triglyceride Level, Porphyria * Undiagnosed abnormal genital bleeding * Androgen dependant tumour * Is Allergic to anabolic androgenic steroid. * Smoker.